(redirected from Requip XL)
Also found in: Medical.


A dopamine agonist, C16H24N2O, used in its hydrochloride form to treat Parkinson's disease and restless legs syndrome.

[(p)rop(yl) + (am)in(o) + -ir- (probably alteration of (h)y(d)r(o)-) + (ind)ole.]


n ropinirol m
References in periodicals archive ?
In the regional portfolio, ahead of final year results due to be announced on Thursday, GlaxoSmithKline's drug Requip XL was again in the spotlight.
The agency set more conditions to be met before it can clear the longer-lasting formulation, Requip XL, to treat symptoms of the neurological disorder.
c) Mirapex ER and Pramipexole, Requip XL and Ropinirole
For the drug-class leaders pramipexole (Boehringer Ingelheim's Mirapex, other brands, generics; Mirapex ER, other brands) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL, other brands, generics), growing reliance on convenient once-daily formulations is expected to render the original, three-times-daily formulations nearly obsolete by the second half of the 2012-2022 forecast period.
Actavis believes this is the first generic Requip XL available in the US.
Azilect, along with levodopa and the dopamine agonists pramipexole (Boehringer Ingelheim's Mirapex ER, Mirapex, generics) and ropinirole (GlaxoSmithKline's Requip XL, Requip, generics) are mainstay treatments in the Parkinson's disease treatment algorithm, with the three-times-daily formulations of the dopamine agonists experiencing greater use among recently treated patients than their once-daily counterparts, according to claims data analysis.
GlaxoSmithKline's Requip XL, for example, showed relatively constant first-line therapy use among newly diagnosed patients and Boehringer Ingelheim's Mirapex ER has seen its patient share increase among the same patient population.
How did the launch of generics impact the reimbursement of GlaxoSmithKline's Requip XL (ropinirole) and Boehringer Ingelheim's Mirapex (pramipexole), and how will it affect the reimbursement of the extended-release formulations of these branded drugs?
Requip XL Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients' "Off" Time by Nearly Two Hours Per Day
Previously, XenoPort was entitled to detail Requip XL commencing upon its exercise of the co-promotion option and ending upon the launch of Solzira.
Key Approvals Filings Phase III commenced Altabax/Altargo Avodart plus alpha 1838262 (RLS) (US & EU) blocker co-prescription (US & EU) Arixtra ACS (EU) Cervarix (US) Belimumab (SLE) Veramyst (US) Gepirone ER (US) Elesclomol (STA- 4783) (melanoma) Cervarix (EU) H5N1 (EU) MAGE-A3 therapeutic vaccine (NSCLC) ReQuip XL (EU) Lunivia (EU) MenACWY-TT meningitis vaccine Seretide TORCH Volibris (EU) Ofatumumab (RA) (EU) Tykerb (US) Requip XL (PD) (US) Promacta (hep c) Wellbutrin XR (EU) Rotarix (US) Tykerb (H&N cancer) Tykerb + Pazopanib (IBC)